NCT01566877View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Marburg Hemorrhagic Fever
Interventions
DRUG

AVI-7288

"Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."

OTHER

Placebo

Normal Saline Solution (NSS)

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Inc., Baltimore

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT01566877 - A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter